- Conditions
- Osteoarthritis, Knee, Knee Osteoarthritis, Knee Pain Chronic
- Interventions
- Resiniferatoxin, Zilretta, Placebo
- Drug
- Lead sponsor
- Sorrento Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 6
- States / cities
- La Mesa, California • Pasadena, California • Oak Brook, Illinois + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–4
of 4
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Breast Cancer
- Interventions
- Bevacizumab 7.5 and TAC, Placebo 7.5 and Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), Bevacizumab 15 and TAC, Placebo 15 and TAC
- Drug
- Lead sponsor
- Translational Oncology Research International
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Pomona, California • Orlando, Florida + 2 more
- Conditions
- Atopic Dermatitis
- Interventions
- Placebo, Upadacitinib, Topical corticosteroids (TCS)
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 1,533 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 59
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 51 more
- Conditions
- Kidney Transplantation
- Interventions
- CFZ533 - Cohort 1/Cohort 2, Mycophenolate Mofetil (MMF), Corticosteroids (CS), Tacrolimus, Induction therapy: basiliximab, Induction therapy: rabbit anti-thymocyte globulin (rATG), Maintenance population: EC-MPS, Maintenance population: MMF, Placebo 1 mL
- Biological · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 418 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 15
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more